Page last updated: 2024-11-02

pargyline and Hormone-Dependent Neoplasms

pargyline has been researched along with Hormone-Dependent Neoplasms in 4 studies

Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.

Research Excerpts

Excerpt	Relevance	Reference
" Among the steroid substrate analogs, 4-hydroxyandrostenedione has been shown to be effective in breast cancer patients with advanced disease and was recently approved for treatment in the United Kingdom."	4.78	Aromatase, its inhibitors and their use in breast cancer treatment. ( Brodie, AM, 1993)

2 reviews available for pargyline and Hormone-Dependent Neoplasms

Article	Year
Aromatase, its inhibitors and their use in breast cancer treatment. Pharmacology & therapeutics, 1993, Volume: 60, Issue:3 Topics: Aminoglutethimide; Androstenedione; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast N	1993
Aromatase and aromatase inhibitors: from enzymology to selective chemotherapy. Progress in clinical and biological research, 1988, Volume: 262 Topics: Androstenedione; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplas	1988

2 other studies available for pargyline and Hormone-Dependent Neoplasms

Article	Year
KDM1A triggers androgen-induced miRNA transcription via H3K4me2 demethylation and DNA oxidation. The Prostate, 2015, Jun-15, Volume: 75, Issue:9 Topics: Acetylcysteine; Cell Line, Tumor; DNA, Neoplasm; Histone Demethylases; Histones; Humans; Kallikreins	2015
Inhibition of growth and appearance of estrogen-dependent rat mammary tumors by 10-propargylestr-4-ene-3,17-dione, an aromatase inhibitor. Breast cancer research and treatment, 1993, Volume: 26, Issue:1 Topics: 9,10-Dimethyl-1,2-benzanthracene; Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibit	1993